Pharmaceutical News

RSS

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.

18 Nov 2014

Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

The type 3 interferons - usually called the “lambda” interferons, or “IFNL” - are the most recently identified IFNs. We (myself and Sergei Kotenko) originally identified the receptor and then the three ligands (IFNL1,2,3; very recently a fourth, IFNL4, was discovered); the key paper was published in 2003.

18 Nov 2014

Investigational treatment shows promise against Marfan syndrome

An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta.

18 Nov 2014

Early sodium supplementation improves weight gain in premature infants

Early sodium supplementation for very premature infants can enhance weight gain according to a recent study by researchers at the University of Cincinnati Medical Center and Cincinnati Children's Hospital Medical Center.

18 Nov 2014

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient).

18 Nov 2014

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).

18 Nov 2014

New research suggests potential role for MEK inhibitors in type 2 diabetes

A research team led by Brigham and Women's Hospital and Dana-Farber Cancer Institute has uncovered surprising new findings that underscore the role of an important signaling pathway, already known to be critical in cancer, in the development of type 2 diabetes.

18 Nov 2014

Omega-3 fatty acids decrease risk of getting heart disease

Increasing the amount of omega-3s in your diet, whether from fish or flax, will likely decrease your risk of getting heart disease, according to Penn State nutritionists.

18 Nov 2014

Uber brings on-demand flu prevention to Chicago

In partnership with Vaccine Finder, Uber is bringing on-demand flu prevention to Chicago. UberHEALTH helps Chicagoans stay healthy this season with flu prevention packs on demand TODAY, Nov. 18 from 10 am until 4 pm CST for free.

18 Nov 2014

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno's collaboration partner, Memorial Sloane Kettering Cancer Center.

18 Nov 2014

IntelliCap electronic oral drug delivery technology wins prestigious European ‘High-Tech Innovation Award’

The IntelliCap electronic oral drug delivery technology, created by medtech innovator Medimetrics, has won a prestigious European ‘High-Tech Innovation Award’ from Accenture, the global management consultancy.

18 Nov 2014

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

The pros and cons of medical marijuana is a discussion focus at the fifth annual Queensland Epilepsy Symposium, Epilepsy – On the Horizon.

18 Nov 2014

MUHC study examines effect of regular re-evaluation of antibiotic use on cost, C. difficile infection rates

Resistance to antibiotics is an important health concern that affects both the spread of infections, like Clostridium difficile, and the medication budget. Researchers at the McGill University Health Centre examined the effectiveness of adopting an antibiotic "time-out" during treatment, which involves regularly re-evaluating the treatment strategy as the clinical situation evolves.

18 Nov 2014

Study suggests that beta blockers may benefit patients suffering from HFPEF

A novel registry study from Karolinska Institutet in Sweden suggests that beta blockers may benefit also patients suffering from a relatively unknown form of heart failure called HFPEF, which today lacks well-established treatment.

17 Nov 2014

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Researchers at the University of Texas Medical Branch at Galveston, in collaboration with The University of Texas Health Science Center at Houston (UTHealth), Baylor College of Medicine and the Georgia Regents University, report for the first time that the cholesterol-lowering drug simvastatin inhibits the growth of human uterine fibroid tumors.

16 Nov 2014

Pharmaceutical News

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

Investigational treatment shows promise against Marfan syndrome

Early sodium supplementation improves weight gain in premature infants

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

New research suggests potential role for MEK inhibitors in type 2 diabetes

Omega-3 fatty acids decrease risk of getting heart disease

Uber brings on-demand flu prevention to Chicago

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

IntelliCap electronic oral drug delivery technology wins prestigious European ‘High-Tech Innovation Award’

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

MUHC study examines effect of regular re-evaluation of antibiotic use on cost, C. difficile infection rates

Study suggests that beta blockers may benefit patients suffering from HFPEF

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Solgar voluntarily recalls ABC Dophilus Powder

Valeant Pharmaceuticals hosts ribbon-cutting ceremony to celebrate renovation of U.S. headquarters in NJ

People treated with lithium drug are at risk of acute kidney damage

Smart drug Modafinil can impair cognitive performance in healthy students

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News